DIAN-TU Primary Prevention Trial for dominantly inherited Alzheimer’s disease
Official title: DIAN-TU Primary Prevention Trial
Funded at Washington University · NIH-11579123 · Data updated 2026-11-12
This trial tests a preventive treatment in people who are genetically at high risk for Alzheimer’s disease but who show no or minimal symptoms yet.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 15, 2018 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $104,277 |
| NIH project number | 3R01AG059798-06S5 |
| Project ID | NIH-11579123 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with a dominantly inherited Alzheimer’s disease mutation, who are asymptomatic or minimally affected and 11–25 years from expected symptom onset, with minimal brain amyloid at entry.
✕Less likely to help
Patients without a DIAD mutation or those who are already showing significant cognitive symptoms are unlikely to benefit.
What this research studies
The DIAN-TU platform, now operating in many countries and sites, is designed to run interventional trials for people with dominantly inherited Alzheimer’s disease (DIAD). This specific primary prevention trial enrolls 160 asymptomatic mutation carriers who are 11 to 25 years from typical symptom onset, and compares a therapy called remternetug against placebo in a multi-stage, blinded design. The study aims to determine whether removing amyloid plaques early can delay or prevent cognitive decline in this high-risk group. Participants will be monitored for safety and cognitive changes as the trial progresses through its stages.
Why it matters
Potential benefit: If successful, this research could delay or prevent dementia in people with DIAD and inform prevention strategies for broader Alzheimer’s disease.
How similar studies have gone: Previous amyloid-removal studies have shown reduced decline in some contexts, supporting exploration of pre-symptomatic intervention, but this trial is pioneering a primary prevention approach in DIAD.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Mcdade, Eric Martin — Washington University
- Study coordinator: Mcdade, Eric Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.